Return to search results.
Complete title: Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®
|Research Study Number||2007.00|
|Principal Investigator||Lauri Burroughs, MD|
Research Study Description
Most of the treatment will be given at the Seattle Cancer Care Alliance (SCCA) outpatient clinic. Initial in-hospital treatment will be given at the University of Washington Medical Center or Childrens Hospital and Regional Medical Center.
Treatment on the study will last about four months (about one month before the transplant and three months after the transplant), but could be longer. Participants may be asked to return for follow-up visits 6 months, and then every year, after the transplantation.
Additional bone marrow or blood samples may be drawn at various time points for up to five years after the transplant.
Eligibility Criteria (must meet the following to participate in this study)
Diagnosed with an immunodeficiency or other non-malignant disease that is treatable by allogeneic stem cell transplantation.
Patients with pre-existing medical conditions or other factors that rule out treatment with conventional myeloablative stem cell transplantation.
Other eligibility criteria may apply.
Exclusions (conditions that would prevent participation in this study)
55 years or older
Patient has HIV
Patient is a female who is pregnant or breast-feeding
Other exclusion criteria may apply.
Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Immunodeficiency Syndromes; Severe Combined Immunodeficiency Syndrome (SCID); Non-malignant Condition
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.